Value in Health

Papers
(The H4-Index of Value in Health is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Author Reply86
When Do Value-Based Contracts Add Value? Insights From Probabilistic Simulations86
CO107 Assessing Short and Long-Term Outcomes in Drug-Associated Acute Kidney Injury82
EE52 The Burden of Intravenous vs Subcutaneous Oncological Products Application in Honduras76
CO67 Network Meta-Analysis to Compare the Efficacy Between Different Classes of PCSK9 Inhibitors, siRNA Vs. PCSK9 mAb, in Asian Patients With Hypercholesterolemia at Increased Cardiovascular Risk74
EPH156 Multimorbidity and Its Associations with Adverse Cardiovascular Events and Healthcare Costs Among Patients with Atherosclerotic Cardiovascular Disease: A Real-World Evidence Study72
EE181 Impact of Type 1 Diabetes on Productivity and Out-of-Pocket Costs of Adult Continuous Glucose Monitoring Users in the United States: Results From a Cross-Sectional Survey in the United States70
EE105 Cost-Effectiveness Analysis of Linperlisib for Relapsed or Refractory Follicular Lymphoma Based on Matching Adjusted Indirect Comparison in China66
EE266 The Economics Promises of a Cure: Best Practices to Guide Economic Negotiations for the Reimbursement of Curative Therapies for Cancer62
EE310 The Burden of Blood Transfusions Associated With Lower-Risk Myelodysplastic Syndromes (LR-MDS): Findings From a Survey of Health Care Professionals (HCPs) in Brazil, Germany, and Japan60
EPH175 Assessment of Streptococcus Pneumoniae as Cause of Acute Otitis Media in Young Children in Colombia: A Prospective Study58
EE311 Exploring Environmental Impacts of Switching Salmeterol/Fluticasone Propionate (SAL/FP) from Metered Dose Inhaler (MDI) to Dry Powder Inhaler (DPI) in Respiratory Illness in the United Kingdom56
EE106 Cost-Effectiveness Analysis of Belimumab for the Treatment of Adults With Active Lupus Nephritis in China53
EPH190 Trends and Disparities in Perinatal Health Outcomes Among Women from Refugee Backgrounds in Victoria, Australia: A Population-Based Study51
EE79 Real-World Clinical and Economic Burden of Primary Biliary Cholangitis in the United States50
EE258 Cost-Effectiveness of Transcatheter Aortic Valve Implantation (TAVI) for High-Risk Patients in Chile49
EE226 Productivity Loss Among Persons With Multiple Sclerosis Treated With Ocrelizumab Vs Other Disease-Modifying Therapies48
EPH115 Sex Differences on Limitations in Physical Functioning and Overall Quality of Life of People Living with Myasthenia Gravis from the MGFA Global MG Patient Registry (MGFAPR) in the US45
HSD25 Patients’ Rare Disease Diagnoses and Their Impact on Physicians’ Emotions: A Cross-Sectional Study in the United States44
HPR38 Estimating the Outcome Disparities in BIPOC and Economically-Disadvantages Patients With Systemic Lupus Erythematosus (SLE)41
EPH27 The Efficacy of Interventions Utilized in Communicating Risk Information to Improve Behavioral Outcomes Among Individuals Who Are Genetically Predisposed of Type 2 Diabetes: A Systematic Review41
RWD135 Right-Sided vs Left-Sided Colorectal Cancer Hospitalization Outcomes in the US40
PCR222 Comparison of Recanalisation Therapies in Terms of Quality of Life in Ischaemic Stroke Patients in Hungary40
PCR207 Health-Related Quality of Life and Its Associate Factors Among Residents in Tianjin, China: Findings from 2023 National Health Service Survey38
CO210 An Updated Systematic Review and Network Meta-Analysis on Risks of Respiratory Tract Infections with Biologic and Targeted Synthetic Antirheumatic Agents in Psoriatic Arthritis38
SA48 Methods to Account for the Impact of COVID-19 in Real-World Retrospective Studies of Economic Outcomes: A Targeted Literature Review37
PT4 Will the IRA's Negotiation Timelines Delay Access to Drugs for Orphan Indications?37
EPH222 Trends of Mortality Related With Dengue in Colombia 2012-202137
EE481 Long-Term Cost-Effectiveness of Tirzepatide Versus Placebo for Individuals With Type 2 Diabetes and Obesity36
SA13 Approaches to Electronic Health Records Notes Selection: Considerations for Best Practices36
P7 Costs and Health Care Resource Utilization Associated with Negative Symptoms Among Patients with Schizophrenia in the United States36
CO18 Impact of Empiric Treatment Failure on Healthcare Resource Utilization and Costs Among Females With Uncomplicated Urinary Tract Infections in a US-Based Integrated Health Delivery Network35
P53 Validation of AI-Generated Synthetic Data for Outcomes Research: A Clinico-Genomics Case Study35
CO49 Progression of Chronic Kidney Disease Among Older Adults with Hypertension Using Group-Based Trajectory Modeling34
0.10441708564758